ISPOR 2024 Home
  • About
    • News Center
  • Award Winners
  • Program
    • Program
    • Learning Formats
    • Plenary Sessions
    • Posters
    • Program Committee
    • Digital Conference Pass
  • Exhibits & Sponsorship
    • Sponsor List
    • Exhibitor Directory
    • Media Partners
  • Photo Gallery
large-circle

ISPOR 2024

May 5-8, 2024

  • Home
  • Events
  • Past Conferences
  • ISPOR 2024
  • Program
  • Program
  • Session

  • Economic Evaluation for the United States (US) of the Overall Survival Analysis of Cemiplimab Plus Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer (NSCLC) With at Least 50% PD-L1 Positivity

    May 6, 2024, 11:30 AM
  • «
  • 1721
  • 1722
  • 1723 (current)
  • 1724
  • 1725
  • 1726
  • 1727
  • 1728
  • 1729
  • 1730
  • »
Quick Links
  • Membership
  • Upcoming Meetings
  • Exhibits & Sponsorships
  • Good Practices Reports & More
  • Value in Health
  • Contact Us
Policies & Legal
  • AI Policy
  • Antitrust Compliance
  • Code of Ethics
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions

Site Map

Media/Press

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group